Tanaka I, Masuda R, Furuhata Y, Inoue M, Fujiwara M, Takemura T
Department of Thoracic Surgery, Japanese Red Cross Medical Center, Tokyo, Japan.
Cancer. 1995 May 15;75(10):2461-5. doi: 10.1002/1097-0142(19950515)75:10<2461::aid-cncr2820751011>3.0.co;2-d.
To assess the prognostic value of DNA ploidy in adenocarcinoma of the lung, the authors performed a flow cytometric study using paraffin embedded archival material from 160 patients (109 [68%] with aneuploid lesions, 51 [32%] with diploid lesions) who underwent surgical resection from 1982 to 1991.
The proportion of DNA aneuploid tumors increased as the disease stage advanced, from 35 of 63 (55.5%) with Stage 1 disease to 15 of 20 (75.0%) with Stage 2 disease, to 40 of 53 (75.5%) with Stage 3a disease, to 19 of 24 (79.2%) with Stage 3b disease. However, this trend was not statistically significant. Comparison of the survival time of the 160 patients with adenocarcinoma of the lung with a median follow-up of 7.8 years revealed that patients with diploid tumors had significantly longer survival than did those with aneuploid tumors (P < 0.01).
Examination by stage showed that patients with Stage 1 disease with diploid tumors had significantly longer survival times than did those with aneuploid tumors (P < 0.05) but that there were no significant differences in clinical outcome in patients with Stage 2, 3a, and 3b diploid tumors.
Analysis of aneuploid versus diploid DNA content in patients with Stage 1 adenocarcinoma of the lung is concluded to be useful in evaluating clinical outcome and prognosis.
为评估DNA倍体在肺腺癌中的预后价值，作者使用1982年至1991年间接受手术切除的160例患者（109例[68%]为非整倍体病变，51例[32%]为二倍体病变）的石蜡包埋存档材料进行了流式细胞术研究。
随着疾病分期的进展，DNA非整倍体肿瘤的比例增加，从I期疾病的63例中的35例（55.5%）增加到II期疾病的20例中的15例（75.0%），再到IIIA期疾病的53例中的40例（75.5%），最后到IIIB期疾病的24例中的19例（79.2%）。然而，这种趋势没有统计学意义。对160例肺腺癌患者进行中位随访7.8年的生存时间比较显示，二倍体肿瘤患者的生存期明显长于非整倍体肿瘤患者（P<0.01）。
按分期检查显示，I期二倍体肿瘤患者的生存时间明显长于非整倍体肿瘤患者（P<0.05），但II期、IIIA期和IIIB期二倍体肿瘤患者的临床结局无显著差异。
对I期肺腺癌患者的非整倍体与二倍体DNA含量进行分析，有助于评估临床结局和预后。
